drugset
drugset / Trial / NCT04974879

Osimertinib Combined With Bevacizumab in the Treatment Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions Metastatic Non-Small Cell Lung Cancer

NCT04974879 ↗

Phase 2 Unknown 20 enrolled Qingdao Central Hospital
NaSingle-groupOpen-labelTreatment

Summary

There is no muture method to treat EGFR 20 insertion mutation non-small-cell lung cancer (NSCLC). the he purpose of this study is to study osimertinib combined with bevacizumab in the management of it.

Timeline

Start
2021-07-01
Primary completion
2024-07-31
Completion
2024-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Bevacizumab Monoclonal antibody 15 mg/kg Intravenous
Subject Osimertinib Small molecule 80 mg Oral

Indications

non-small cell lung carcinoma